Transcode Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director Magda Marquet reports the acquisition of stock options in Transcode Therapeutics.
NASDAQ
Director Erik Manting acquired 70,000 stock options in Transcode Therapeutics, Inc. on June 14, 2024.
NASDAQ
Thomas A. Fitzgerald, Interim CEO and CFO of Transcode Therapeutics, acquired 650,000 stock options on June 14, 2024.
NASDAQ
Director Calais Philippe reports the acquisition of stock options in Transcode Therapeutics, Inc.